Trade-offs between safety & efficacy when discussing 1st line RCC

Trade-offs between safety & efficacy when discussing 1st line RCC

User Photo
obr

2 years
41 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Robert A. Figlin, MD, explains the trade-offs between safety and efficacy when discussing first-line renal cell carcinoma (RCC) treatment options.
Up Next Autoplay
>